Full Title
FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration (Advarra IRB)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Gopakumar Iyer’s office at 646-888-4737
Protocol
26-039
Phase
Phase III (phase 3)
Disease Status
Newly Diagnosed
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT07218380